首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

2050967

遺傳性血管性水腫市場：按類型、藥物類別、給藥途徑、通路和地區分類

Hereditary Angioedema Market By Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，遺傳性血管性水腫市場在 2026 年的價值為 34.4 億美元，預計到 2033 年將達到 66.1 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 9.8%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	34.4億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	9.80%	2033年市場規模預測：	66.1億美元

遺傳性血管性水腫是一種罕見的遺傳性疾病，其特徵是反覆出現嚴重的皮下或黏膜下水腫。症狀包括手、腳、四肢、臉部、胃腸道和呼吸道的腫脹。這些水腫發作是由C1抑制劑水平降低或功能障礙引起的，C1抑制劑是一種血清蛋白，在調節補體系統和纖溶系統的特定部分中發揮作用。平均而言，遺傳性血管性水腫患者每四周至少會經歷一次水腫發作，通常需要醫療干預來控制症狀。全球盛行率的不斷上升以及人們對現有治療方案認知的不斷提高，可能會推動遺傳性血管性水腫市場的成長。

市場動態

治療方法研究的進展、全球遺傳性血管性水腫（HAE）盛行率的上升、FDA認證核可藥的普及以及人們對該疾病認知的提高，有望推動遺傳性血管性水腫市場的成長。然而，HAE治療的高昂費用以及開發中國家對該疾病認知度的低可能會阻礙市場成長。皮下注射C1-INH製劑和口服療法的研發為市場參與企業帶來了新的機會。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數創建了全球遺傳性血管性水腫 (HAE) 市場主要公司的概況：公司亮點、產品系列、主要特徵、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份《全球遺傳性血管性水腫市場報告》旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球遺傳性血管性水腫市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

CSL Behring
Sanofi
Takeda Pharmaceutical Company Limited
Orchard Therapeutics plc.
Pharming Group NV
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Attune Pharmaceuticals
Arrowhead Pharmaceuticals, Inc.
Adverum Biotechnologies, Inc.
KalVista Pharmaceuticals
CENTOGENE NV

第10章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第11章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI1292

Hereditary Angioedema Market is estimated to be valued at USD 3.44 Bn in 2026 and is expected to reach USD 6.61 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3.44 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.80%	2033 Value Projection:	USD 6.61 Bn

Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of intense subcutaneous or submucosal edema. Symptoms include episodes of swelling in the hands, feet, limbs, face, intestinal tract and airway. The episodes are caused by decreased levels or functioning of C1 inhibitor, which is a serum protein responsible for regulating certain parts of the complement and fibrinolytic systems. Patients with hereditary angioedema experience episodes of edema at least once every 4 weeks on average and commonly require medical intervention for symptom management. Increasing prevalence of disease globally and rising awareness about available treatment options can drive the hereditary angioedema market growth.

Market Dynamics

Increasing research into treatment alternatives, rising prevalence of HAE globally, availability of FDA approved drugs and growing awareness about the disease can drive the hereditary angioedema market growth. However, high costs associated with HAE therapies and lack of awareness in developing countries can hamper the market growth. Development of subcutaneous C1-INH products and oral treatments offers new opportunities for the market players.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global hereditary angioedema market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market.

Market Segmentation

By Type Insights (Revenue, USD Bn, 2021 - 2033)
Hereditary Angioedema Type I
Hereditary Angioedema Type II
By Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others
By Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
Subcutaneous
Intravenous
Oral
By Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
CSL Behring
Sanofi
Takeda Pharmaceutical Company Limited
Orchard Therapeutics plc.
Pharming Group N.V.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Attune Pharmaceuticals
Arrowhead Pharmaceuticals, Inc.
Adverum Biotechnologies, Inc.
KalVista Pharmaceuticals
CENTOGENE N.V.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Hereditary Angioedema Market, By Type
- Hereditary Angioedema Market, By Drug Class
- Hereditary Angioedema Market, By Route of Administration
- Hereditary Angioedema Market, By Distribution Channel
- Hereditary Angioedema Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Epidemiology
Pipeline Analysis

4. Hereditary Angioedema Market, By Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hereditary Angioedema Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Hereditary Angioedema Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Hereditary Angioedema Market, By Drug Class, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
C1 Esterase Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Bradykinin Receptor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Attenuated Androgens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Hereditary Angioedema Market, By Route of Administration, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intravenous
Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Hereditary Angioedema Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Hereditary Angioedema Market, By Region, 2021 - 2033, (USD Bn)

Introduction
- Market Share (%) Analysis, 2026,2028 & 2033, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Orchard Therapeutics plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pharming Group N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioCryst Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ionis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Attune Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Arrowhead Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Adverum Biotechnologies, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
KalVista Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CENTOGENE N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies